| Date | Title | Description | Source |
| 10.04.2024 | Pharvaris Reports Fourth Quarter and Full Year 2023 Financia... | RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks... | einpresswi... |
| 06.03.2024 | Pharvaris to Present Deucrictibant Clinical Data at Upcoming... | - | globenewsw... |
| 05.03.2024 | Pharvaris to Participate in the Leerink Global Biopharma Con... | - | globenewsw... |
| 05.01.2024 | Pharvaris Provides Business Update and Outlines 2024 Strateg... | RAPIDe-3, a global Phase 3 clinical study of deucrictibant for the on-demand treatment of HAE, to in... | einpresswi... |
| 06.12.2023 | Leadership changes with some promotions | | startuptic... |
| 06.12.2023 | Pharvaris Announces Pricing of $300 Million Underwritten Off... | - | globenewsw... |
| 06.12.2023 | Why Cerevel Therapeutics has risen 50% in three days without... | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech ne... | statnews.c... |
| 21.07.2023 | Pharvaris Presents Clinical Data at the 2023 U.S. HAEA Natio... | /EIN News/ -- ZUG, Switzerland, July 21, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinic... | einpresswi... |
| 26.06.2023 | Pharvaris obtains $70 million in a private placement round | | startuptic... |
| 20.06.2023 | Pharvaris Announces $70 Million Private Placement Financing | - | globenewsw... |
| 10.06.2023 | Data of Deucrictibant for the On-Demand Treatment of HAE Att... | Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours afte... | einpresswi... |
| 05.04.2023 | Pharvaris Reports Fourth Quarter and Full Year 2022 Financia... | Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 for the prophylactic treat... | einpresswi... |
| 24.08.2022 | Swiss biotechs in dispute with regulators | | startuptic... |
| 22.12.2021 | Pharvaris N : Announces Changes to its Board of Directors - ... | Pharvaris Announces Changes to its Board of Directors
Zug, Switzerland, Dec. 22, 2021 - Pharvaris (N... | marketscre... |
| 22.12.2021 | Pharvaris Announces Changes to its Board of Directors | ZUG, Switzerland, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage compa... | marketscre... |
| 07.12.2021 | Pharvaris Announces Changes to its Board of Directors | ZUG, Switzerland, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage compa... | marketscre... |
| 07.12.2021 | Pharvaris N : Announces Changes to its Board of Directors - ... | Pharvaris Announces Changes to its Board of Directors
Zug, Switzerland, December 7, 2021 - Pharvaris... | marketscre... |
| 10.11.2021 | Pharvaris Reports Third Quarter 2021 Financial Results and P... | RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks, proceeding; topline d... | marketscre... |
| 10.11.2021 | Pharvaris Reports Third Quarter 2021 Financial Results and P... | Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights
• RAPIDe-1, ... | marketscre... |
| 30.07.2021 | Pharvaris N : Reports Second Quarter 2021 Financial Results ... | Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights
• RAPIDe-1,... | marketscre... |
| 10.07.2021 | Pharvaris N : Presents Clinical Data on Oral PHA121 Supporti... | ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage compa... | marketscre... |
| 01.07.2021 | Pharvaris N : to Present PHA121 Clinical Data for Oral Treat... | Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI A... | marketscre... |
| 11.06.2021 | PHARVARIS N.V.
Pharvaris N : Announces Annual Meeting of Sh... | Pharvaris Announces Annual Meeting of Shareholders
Zug, Switzerland, June 11, 2021 - Pharvaris (Nasd... | marketscre... |
| 28.05.2021 | BRAIN BIOTECH AG
BRAIN Biotech : Präsentation Analysten Cal... | BRAIN Biotech AG
Creating a #BiobasedFuture
Analyst Call 6M, FY 2020/'21
Adriaan Moelker, CEO
Lukas ... | marketscre... |
| 26.05.2021 | PHARVARIS N.V.
Pharvaris N : Reports First Quarter 2021 Fin... | Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights
• RAPIDe-1, ... | marketscre... |
| 26.05.2021 | PHARVARIS N.V.
Pharvaris N : Reports First Quarter 2021 Fin... | RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks proceeding
HAE CHAPTER... | marketscre... |
| 14.05.2021 | PHARVARIS N.V.
Pharvaris N : Appoints Wim Souverijns, Ph.D.... | Pharvaris Appoints Wim Souverijns, Ph.D., as
Chief Community Engagement & Commercial Officer
• I... | marketscre... |
| 12.05.2021 | PHARVARIS B.V.
Pharvaris B : Appoints Wim Souverijns, Ph.D.... | Industry veteran with deep commercial experience further strengthens leadership team as company adva... | marketscre... |
| 03.05.2021 | PHARVARIS B.V.
Pharvaris B : Amendment to Current Report by... | Exhibit 99.1
Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
• R... | marketscre... |
| 30.04.2021 | PHARVARIS B.V.
Pharvaris B : Reports Full Year 2020 Financi... | Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
• RAPIDe-1 clini... | marketscre... |
| 21.04.2021 | PHARVARIS B.V.
Pharvaris B : Announces FDA Acceptance of IN... | ZUG, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage comp... | marketscre... |
| 28.02.2021 | 3 New IPOs Trending Higher Heading Into March | February was an active month for IPOs. | forbes.com... |
| 05.02.2021 | Pharvaris goes public and raises $165 million | | startuptic... |
| 05.02.2021 | Pharvaris goes public and raises $165 million | Last November, Pharvaris has closed an oversubscribed $80 million Series C financing bringing its to... | startuptic... |
| 27.01.2021 | Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral... | | prnewswire... |
| 05.01.2021 | Pharvaris Expands Board of Directors with Appointment of Dav... | | prnewswire... |
| 19.11.2020 | Pharvaris Announces $80 Million Series C Financing | | startuptic... |
| 19.11.2020 | Pharvaris Announces $80 Million Series C Financing | Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic condition with sympto... | startuptic... |
| 18.11.2020 | Pharvaris lands another $80M as it looks to tackle Take... | A year after their $66 million launch, the Swiss upstart Pharvaris has managed to convince an... | endpts.com... |
| 18.11.2020 | Pharvaris B.V. announced that it has received $80 million in... | Pharvaris B.V. announced that it has received $80 million in a round of funding co-led by new invest... | marketscre... |
| 18.11.2020 | Pharvaris Announces $80 Million Series C Financing to Advanc... | | prnewswire... |
| 18.11.2020 | Pharvaris Raises $80M in Series C Financing | Pharvaris, a Zug, Switzerland-based clinical-stage company, closed an $80m Series C financing bringi... | finsmes.co... |
